Empowering Clinical Decision Making in Oligometastatic Colorectal Cancer: The Potential Role of Drug Screening of Patient-Derived Organoids by Mauri, Gianluca et al.
case
reports
Empowering Clinical Decision Making in
Oligometastatic Colorectal Cancer: The Potential
Role of Drug Screening of Patient-Derived
Organoids
Gianluca Mauri, MD1,2,3; Erika Durinikova, PhD4; Alessio Amatu, MD1; Federica Tosi, MD1; Andrea Cassingena, PhD1;
Francesco Rizzetto, MD1; Kristi Buzo, MSc4; Pamela Arcella, BSc4,5; Maria Costanza Aquilano, MD1; Emanuela Bonoldi, MD1;
Silvia Marsoni, MD3; Salvatore Siena, MD1,2; Alberto Bardelli, PhD4,5; Andrea Sartore-Bianchi, MD1,2; and Sabrina Arena, PhD4,5
INTRODUCTION
The definition of oligometastatic colorectal cancer
(CRC) identifies a peculiar subpopulation of patients
characterized by a limited metastatic spread of
disease.1 Oligometastatic disease is defined as the
involvement of up to two or occasionally three sites with
five or sometimes more metastases that for their an-
atomic localization is amenable to local ablative
therapies, thus rendering the patient free of disease.1-3
Thus, this subgroup is wide and has a significant
cohort of patients with CRC. Among patients with
oligometastatic CRC, those with liver-limited disease
represent a more refined subset and should always be
discussed in multidisciplinary teams since they appear
to more likely benefit from multimodal approaches
with curative intent.2,4-6 A perioperative systemic
treatment integrated with surgical liver meta-
stasectomy should be regarded as the best multimodal
approach.2,7 However, the best drug regimen to be
adopted for this subset of patients with CRC is still
debatable and should be tailored case-by-case.
Considering left-sided microsatellite stable, RAS and
BRAF wild-type CRC, doublet cytotoxic regimens
(FOLFIRI or FOLFOX) plus an anti-epidermal growth
factor receptor (EGFR) drug can represent the best
option on the basis of significant response rate (RR).8-10
However, triplet cytotoxic regimens FOLFOXIRI plus
bevacizumab or anti-EGFR drug demonstrate an im-
pressive RR up to 87%, which are increasingly
regarded as potential novel neoadjuvant standard
strategies.5,11 However, severe treatment-related tox-
icities have been reported in up to 80% of patients.11,12
Hence, both doublet or triplet combinations and anti-
EGFR or antivascular endothelial growth factor are
feasible options in this subset of patients.
The generation of preclinical models such as patient-
derived organoids (PDOs), recapitulating patient tu-
mor histology and genetics, is emerging as a tool to
predict treatment efficacy in oncology.13,14 Although
genomics has already improved treatment choice in
patients with CRC, especially for those carrying RAS/
BRAF wild type, coclinical trials are becoming more
and more important to directly test different treatment
options in patient-derived tumors.15
Here, we present a proof-of-concept case report about
the potential role of drug sensitivity testing in PDOs in
the clinical decision making of oligometastatic CRC.
TRANSLATIONAL REPORT
In July 2018, a 56-year-old healthy man underwent a
screening colonoscopy and was diagnosed with a left-
sided colonic mass demonstrating a moderately dif-
ferentiated (G2) adenocarcinoma. Afterward, a com-
puted tomography (CT) scan revealed two metastatic
lesions in liver segments VIII and V (Fig 1A). Baseline
carcinoembryonic antigen (CEA) was 15.5 ng/mL, and
cancer antigen (CA) 19.9 was 55 U/mL. Following
multidisciplinary discussion and on the basis of
standard molecular biomarker assessment, demon-
strating microsatellite stability, no mutations in RAS
and BRAF, and no ERBB2 amplification, the patient
received four cycles of neoadjuvant FOLFOX plus
panitumumab (Fig 2). Treatment was complicated by
grade 3 afebrile neutropenia requiring peg-filgrastim
support. No other adverse events occurred.
CT scan reassessment demonstrated partial response
(PR) (Figs 1B and 1E), and thus, following a new
multidisciplinary discussion, in November 2018, the
patient underwent R0 liver metastasectomy and left
emicolectomy. The pathology report described an
ypT3 ypN2b ypM1aG2 adenocarcinoma. At this time,
after signing informed consent and the enrollment in
the AlfaOmega observational trial (NCT04120935), a
fresh tumor sample from the metastatic liver lesion in
segment VIII was used for PDOs generation. Once
established (Data Supplement), these tumoroids un-
derwent histologic analysis, confirming the corre-
spondence and similarity between the PDOs and the
metastatic tissue of origin (Fig 2). The next-generation
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panel on primary left colon lesion, as per GO40782 clinical
trial screening (NCT02568267), revealed no mutations
discriminating for sensitivity to cytotoxic agents.2,6,16 We also
performed whole-exome sequencing analysis on PDOs,
confirming the presence of patient-specific trunk alterations,
whereas no alterations conferring resistance to anti-EGFR
drugs were observed (Fig 2).
Following surgical resection, as per clinical practice, the
patient received further eight cycles of systemic treatment
with FOLFOX regimen supported with peg-filgrastim
prophylaxis, ending in April 2019. The patient tolerated
the postoperative treatment well without relevant side
effects.
Despite this multimodal approach, CT and positron emis-
sion tomography scan in October 2019 showed disease
relapse in liver segments VIII, VII, and V (Fig 1C). Con-
sidering this evidence, the case was discussed collectively
and we also took into consideration the results of a drug
sensitivity testing performed on the PDOs, which, evalu-
ating the most effective agents in this clinical context,
showed complete resistance to oxaliplatin (OXA) but rather
a prominent sensitivity to fluorouracil 5-FU SN-38 (the
active metabolite of irinotecan), panitumumab, and
cetuximab (Fig 3 and Appendix Fig A1). Primarily based on
clinical standard and corroborated by PDOs drug sensitivity
testing, we avoided OXA-based treatment and the patient
was treated with six cycles of FOLFIRI and panitumumab
and peg-filgrastim prophylaxis. This schedule was well-
tolerated, and the following CT scan again demonstrated
a PR (Figs 1D and 1E). Given this result, in March 2020, the
patient underwent multiple liver metastasectomy con-
firming metastatic adenocarcinoma. Thereafter, the patient
received six cycles of postoperative 5-FU, again well-
tolerated. In July 2020, the CT scan demonstrated no
evidence of disease and CEA and CA19.9 were normal. The
following CT scan in October 2020 confirmed no relapse
with normal CEA and CA19.9. The patient has consented to
the submission and the publication of the case report.
DISCUSSION
Our groups have jointly focused their efforts on the de-
velopment of preclinical models with the aim of tailoring
treatment for patients with metastatic CRC on the basis of
the results obtained from the pharmacologic screening on
patients’ avatars.17-24 By taking advantage of patient-
derived xenografts,19 we previously identified optimal
therapeutic regimens for CRC druggable targets such as
ERBB2 amplification.25-27 Recently, the establishment of

























FIG 1. Radiologic evidence of response following FOLFOX plus panitumumab and FOLFIRI plus panitumumab. (A) The venous phase of the baseline
CT scan performed in July 2018 showed a large hypodense lesion in (arrow) segment VIII of the liver. (B) Following four cycles of treatment with
FOLFOX and panitumumab, at CT scan performed on November 2018, a partial response (shrinkage of the longest lesion’s diameter from 38 to
20 mm) of the hepatic lesion in (arrow) segment VIII was observed as well. (C) The venous phase of the CT scan performed in October 2019
demonstrated liver relapse of disease with three new hypodense lesions with peripheral rim enhancement in segment VII, segments V-VIII, and (not
visible) segment V. (D) After six cycles of FOLFIRI and panitumumab, the CT scan performed in January 2020 showed a decrease in lesions’ size:
segment V decrease by 50% (from 12 to 6 mm), segments V-VIII by 37% (from 19 to 12 mm), and segment VII by 33% (from 18 to 12 mm). All lesions
were evaluated as per RECIST1.1 criteria. (E) Bar graph summarizes the best RECIST1.1 response to both first-line treatment with FOLFOX plus
panitumumab (–45%) and second-line treatment with FOLFIRI plus panitumumab (–39%). CT, computed tomography; Pmab, panitumumab.
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tumor biopsy has accelerated the possibility to test drugs on
patients’ avatars,21,23,28 thus offering a valid approach to
test drug sensitivity on the bench, in parallel to patient care.
Here, we report the case of an patient with oligometastatic
CRC whose drug screening on PDOs resembles both re-
sistance and sensitivity to main cytotoxic agents. Most
notably, PDOs drug testing was performed in parallel with
clinical care. This translational paralleling is usually ham-
pered by the time required to establish PDOs and test drug
activity in the continuum of care of CRC (Fig 2). However,
the expected recurrence-free survival following liver re-
section in oligometastatic CRC offers a timely opportunity to
translate the PDOs drug sensitivity testing results into
clinical decision making at relapse. Here, we were able to
identify a medical perioperative regimen with the higher
chance to obtain tumor shrinkage, aiming to offer a second
potentially curative resection to the patient.2,7 Indeed, given
performance status, tumor sidedness, and molecular status,
both a triple cytotoxic regimen composed of FOLFOXIRI
plus bevacizumab and a doublet cytotoxic combination
plus anti-EGFR drug were feasible, reasonably expecting
similar RR.2,12 However, PDO’s pharmacogenomics profile
showing resistance to OXA and sensitivity to 5-FU, SN-38,
and panitumumab supported the clinical choice of FOLFIRI
and panitumumab as perioperative regimen. This led to





















































































































FIG 2. Patient’s oncologic history timeline and histopathologic analysis of the metastatic lesion and of the PDOs. In the light blue background,
representative hematoxylin and eosin images from the metastatic lesion recovered in March 2018 (top panels) and from the organoids derived from this
lesion (lower panels) are given. Furthermore, the table in the light blue background depicts molecular alterations found in genes that are known to play a
key role in colorectal cancer development and are recommended by clinical guidelines to define patients’ treatment. Data were obtained from the NGS
panel (FoundationOne CDx) performed according to GO40782 clinical trial (NCT02568267) screening on archival patient’s left-sided primary tumor
tissue and from the WES performed on PDOs. 5-FU, fluorouracil; Lancet, surgical procedure; MMR, mismatch repair status; MSS, microsatellite stable;
NGS, next-generation sequencing; PDOs, patient-derived organoids; Pmab, panitumumab; PR, partial response; red circle, best response at computed
tomography scan disease reassessment; WES, whole-exome sequencing.
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metastasectomy to improve the chance of cure, sparing
side effects of other intensive cytotoxic regimens.11,29-31
Here, we limited our screening to approved drugs, but
elsewhere, we already proposed rationale combinations
including unapproved therapeutics on the basis of the

























































































































































FIG 3. Patient-derived organoids
show different profiles of sensitivity to
cytotoxic drugs and targeted treat-
ment. (A) Representative bright-field
microscopy images of organoids de-
rived from the oligometastatic patient
treated with OXA and 5-FU for 12
days and with SN-38 and pan-
itumumab for 7 days. MG-132 was
used as a positive control for orga-
noids’ death (data not shown), and
DMSO or DMEM/F12 served as a
negative control. Magnification: 10×.
(B) At the end of the treatment,
organoids’ viability was measured by
the CellTiter GLO assay and numbers
were analyzed using GraphPad soft-
ware. The results are the average of at
least two independent experiments
with technical quadruplicates. Error
bars represent the standard deviation
among biologic replicates. Z factor
values varied between 0.73 and
0.91. ctrl, control; 5-FU, fluorouracil;
OXA, oxaliplatin; Pmab, panitumumab.
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This case report reinforces other recent publications in
which PDOs were suggested as a potential platform to
identify the best treatment for each patient.17 In addition,
we envision the subset of patients with oligometastatic CRC
as the optimal to bypass the limitation given by time re-
quired to PDOs establishment. Prospective translational
trials are needed to verify the feasibility of this translational
approach in peculiar clinical settings (Table 1).
Treatment implementation driven by PDOs drug sensitivity
testing has intrinsic limitations potentially hampering its
applicability in the daily clinical practice. First, limiting
factors such as tumor heterogeneity leading to potential
sampling biases might represent relevant barriers toward
translational applicability. Thus, we hypothesize that
PDOs testing might be more helpful in patients with a low
tumor burden, because of intrapatient heterogeneity that
is expected to be lower in these patients.34,35 Indeed,
diffused metastatic disease is more likely to be widely
heterogeneous and patients do not achieve the same
results observed on PDOs.21,36,37 Second, PDOs drug
sensitivity testing constitutes a relatively expensive
method to choose a systemic cytotoxic regimen. However,
we reasoned that this might be justifiable to maximize the
chance of cure and improve the quality of life. Finally, in
hospitals where a close connection with a preclinical
laboratory is not a reality, PDO-driven approach might be
difficult to be set up.
In conclusion, we provide a translational report demon-
strating that PDOs drug sensitivity testing is feasible and
might represent a valid tool to predict and improve the
choice for the best perioperative personalized approach in
patients with oligometastatic CRC. We suggest indeed that
this setting, because of the time intervals between surgery
and resumption of medical treatment, would offer the best
choice to parallel patients’ care, allowing timely modu-
lation of the treatment strategy. These advantages should
be supported by optimization of protocol standardiza-
tion and balance against costs related to organoid
maintenance.
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Clinical Contexts
Patient in good performance status—potentially a candidate to different medical
systemic treatments
Surgical curative (R0) resections of high-risk primary tumor (T4 or N2 and/or with
additional risk factors for relapse such as ctDNA positivitya)
Surgical curative (R0) resections of metastatic lesions providing adequate
samples for PDOs generation
Expected recurrence-free survival after surgery allowing PDOs establishment and
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conversion therapy)
In the metastatic setting, no intervening therapies, containing drugs to which the
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FIG A1. The response of patient-derived organoids to the anti-EGFR monoclonal antibody cetuximab. (A) Representative bright-field microscopy images
of organoids treated with cetuximab for 7 days. MG-132 was used as a positive control for organoids’ death (data not shown), whereas DMEM/F12medium
served as a negative control. Magnification: 10×. (B) At the end of the treatment, organoids’ viability was measured by the CellTiter GLO assay and viability
values were analyzed using GraphPad software. The results are the average of three independent experiments with technical quadruplicates, and error
bars represent the standard deviation among biologic replicates. Z factor values varied between 0.75 and 0.82. Cmab, cetuximab; ctrl, control.
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